bioRxiv Science⌕ Search

Biology subjects

Dubrac, A.

Publications and source records attributed to Dubrac, A..

3 recordsLinked to original sources

SOX9 regulates endothelial tip cell specification to promote cerebral and neuroretinal vascularization

BackgroundTissue vascularization relies on the organotypic specification of endothelial tip cells to interpret local cues and guide angiogenic sprouts into specific tissue compartments. However, the molecular regulators controlling brain and retinal endothelial tip cell identity remain poorly understood. MethodsEndothelial-specific Sox9 loss-of-function mouse was combined with single-cell, spatial, and bulk RNA sequencing analyses of developing mouse brain and retinal vasculature, as well as experimental ischemic stroke. Transcriptomic findings were validated using in situ hybridization, immunofluorescence, and functional angiogenesis assays. ResultsTranscription factor activity analysis of single-cell RNA-sequencing datasets identified SOX9 as a candidate regulator selectively enriched in developing brain and retinal endothelial tip cells. Endothelial-specific deletion of Sox9 impaired brain and neuroretina vascularization and disrupted the tip cell transcriptomic program, resulting in reduced sprouting angiogenesis and matrix-remodeling pathways. Conversely, SOX9 overexpression in HUVECs promoted neuro-tip-like signatures and enhanced endothelial invasion and sprouting. Following ischemic stroke, single-cell and spatial transcriptomic analyses identified a transient angiogenic endothelial population within the ischemic area. However, these cells failed to express Sox9 and lacked key developmental brain tip cell features. ConclusionsSOX9 is a key regulator of endothelial tip cell identity and neuronal angiogenesis. These findings reveal fundamental differences between developmental and injury-induced vascular responses and identify SOX9 as a potential therapeutic target to promote functional vascular regeneration.

developmental biology↗

Loss of endothelial ALK1 signaling induces the emergence of a KIT+ angiogenic endothelial cluster driving brain arteriovenous malformations

BackgroundHereditary Hemorrhagic Telangiectasia type 2 (HHT2) is a genetic disorder caused by mutations in the ALK1 (ACVRL1) gene, encoding a receptor for Bone Morphogenetic Proteins 9 and 10 (BMP9/BMP10). HHT2 patients frequently develop brain arteriovenous malformations (bAVMs), which are abnormal connections between arteries and veins. Currently, surgical resection is the only treatment, associated with significant risks and complications. Despite evidence suggesting endothelial cell (EC) heterogeneity in bAVMs, it remains poorly characterized, limiting our ability to identify new therapeutic avenues. MethodsWe employed endothelial cell-specific and inducible Alk1 knockout mice (Alk1iECKO) with tamoxifen-induced deletion at postnatal day 6 (P6). We separately analyzed the P8 perineural (PNVP) and intraneural (INVP) vascular plexuses, which differ in vessel composition and flow dynamics. Single-cell RNA sequencing (scRNAseq) was performed to characterize EC heterogeneity and identify transcriptomic changes in both vascular plexuses of mutant versus wild type mice. ResultsLoss of endothelial ALK1 signaling triggered bAVM formation predominantly in the PNVP vascular network. scRNAseq revealed that Alk1 deletion promoted brain capillaries differentiation into angiogenic-1 ECs, whereas it drove PNVP venules EC proliferation and the emergence of the unique angiogenic-2 cluster. The latter shares transcriptomic features with human AVM ECs, including angiogenic tip cell markers and a strong glycolytic signature. Among its defining markers, Kit emerged as a direct downstream target of BMP9-ALK1 signaling. Pharmacological KIT inhibition using Masitinib, Imatinib, or KIT-blocking antibodies prevented bAVM formation in Alk1iECKO mice. ConclusionOur study uncovers a previously unrecognized EC population, the angiogenic-2 cluster, as a key contributor to bAVM development. We identify Kit as a central regulator of this cluster, establishing it as a promising therapeutic target for preventing bAVMs in HHT2. Clinical PerspectiveO_ST_ABSWhat is new?C_ST_ABSO_LIUsing endothelial-specific Alk1 knockout mouse models and single-cell transcriptomics, we identified a novel angiogenic endothelial cell population as a key driver of brain AVM formation. C_LIO_LIThis angiogenic EC cluster shares molecular features with human bAVM cells, including high expression of KIT, which we identified as a new direct transcriptional target of BMP9-ALK1 signaling. C_LIO_LIPharmacological inhibition of KIT using small molecules or blocking antibodies effectively prevents AVM formation in vivo, establishing KIT as a promising therapeutic target. C_LI What are the clinical implications?O_LIOur findings support the therapeutic potential of targeting KIT with FDA-approved drugs such as Imatinib to treat HHT2-associated brain AVMs, offering a non-invasive alternative to surgical intervention. C_LIO_LICharacterizing AVM-specific endothelial subtypes may enable the development of targeted and personalized therapies, improving patient outcomes and minimizing treatment-associated risks in HHT. C_LI

cell biology↗

Metabolic Reprogramming of the Neovascular Niche Promotes Regenerative Angiogenesis in Proliferative Retinopathy

Healthy blood vessels supply neurons to preserve metabolic function. In blinding ischemic proliferative retinopathies (PRs), pathological neovascular tufts often emerge in lieu of needed physiological neuroretina revascularization. We show that metabolic shifts in the neurovascular niche define this angiogenic dichotomy between healthy and diseased blood vessel growth. Fatty acid oxidation (FAO) metabolites accumulated in human and murine retinopathy samples. Neovascular tufts with a distinct single-cell transcriptional signature highly expressed FAO enzymes. The deletion of Sirt3, an FAO regulator, shifted the neurovascular niche metabolism from FAO to glycolysis and suppressed tuft formation. This metabolic transition increased Vegf expression in astrocytes and reprogrammed pathological EC to a physiological phenotype, hastening vascular regeneration of the ischemic retina. Our findings identify SIRT3 as a metabolic switch in the neurovascular niche, offering a new therapeutic target for optimizing ischemic tissue revascularization. HighlightsO_LIPathological EC favor FAO over glycolysis. C_LIO_LIUnique signature for pathological EC found in proliferative retinopathy model. C_LIO_LISirt3 deletion shifts astrocytes and EC metabolism from FAO to glycolysis. C_LIO_LIMetabolic reprogramming of the vascular niche enhances physiological revascularization. C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=83 SRC="FIGDIR/small/566898v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@70020eorg.highwire.dtl.DTLVardef@19719acorg.highwire.dtl.DTLVardef@1168ddeorg.highwire.dtl.DTLVardef@1bc25e0_HPS_FORMAT_FIGEXP M_FIG C_FIG

cell biology↗